Purdue Pharma L.P.

Type: Company
Name: Purdue Pharma L.P. (Purdue Pharma L.P)
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

US Patent Issued to Purdue Pharma on Aug. 19 for "Encased Tamper Resistant Controlled Release Dosage Forms" (New Jersey Inventor)

ALEXANDRIA, Va., Aug. 19 -- United States Patent no. 8,808,740, issued on Aug. 19, was assigned to Purdue Pharma LP (Stamford, Conn.)."Encased tamper resistant controlled release dosage forms" was invented by Haiyong Hugh Huang (Princeton, N.J.).According ... [Published HighBeam Research - Aug 20 2014]
First reported Aug 09 2014 - Updated Aug 09 2014 - 1 reports

Butrans Transdermal System CIII receives new dosage strength approval

Purdue Pharma has announced that the FDA approved a new 7.5mcg/hour dosage strength of Butrans (buprenorphine) Transdermal System CIII. Five strengths of Butrans now will be available: 5mcg/hour, 7.5mcg/hour, 10mcg/hour, 15mcg/hour and 20mcg/hour. The ... [Published Center Watch - Aug 09 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Marijuana Legalization: Pharmaceuticals, Alcohol Industry Among Biggest Opponents Of Legal Weed

Opponents of marijuana legalization argue that decriminalizing pot increases crime, creates juvenile delinquents and can even lead to more marijuana-related deaths. But there is another reason for the crusade against marijuana that involves some people ... [Published International Business Times - Aug 06 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Justin Chickles Joins myoscience as Vice President of Commercial Development & Johanna Beckmen Becomes General Manager of Aesthetics

REDWOOD CITY, Calif., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Myoscience, Inc. is pleased to announce the addition of Justin Chickles to the team as Vice President of Commercial Development and the promotion of Johanna Beckmen to General Manager of Aestheti ... [Published Stock Nod - Aug 06 2014]
First reported Aug 03 2014 - Updated Aug 03 2014 - 1 reports

New painkiller created to discourage abuse

As Pennsylvania lawmakers continue to mull uses of naloxone, the Food and Drug Administration has approved a new extended-release pill that combines oxycodone with the widely hailed “miracle drug” used to reverse the effects of an overdose of an opiate ... [Published Delco Times - Aug 03 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

FDA Approves Purdue Pharma’s Abuse-Deterrent Painkiller

The FDA approved only the second extended-release opioid painkiller to feature abuse-deterrent properties, and hinted that future products with such technologies could receive faster regulatory reviews.Purdue Pharma’s Targiniq ER (oxycodone HCl and naloxone ... [Published FDA News - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

FDA Grants Priority Review Designation for Purdue Pharma's Once-Daily Hydrocodone Bitartrate Extended-Release Tablets Formulated with Abuse-Deterrent Properties

By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) has granted Priority Review designation for the company's once-daily, single-entity hydrocodone bitartrate ... [Published HighBeam Research - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Global Infection Prevention and Control Market : 2014-2018

Press ReleaseTechNavio Announces the Publication of its Research Report - Global Infection Prevention and Control Market 2014-2018TechNavio recognizes the following companies as the key players in the Global Infection Prevention and Control Market: Belimed ... [Published MarketResearch.com - Jul 29 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

FDA Approves Purdue Pharma L.P.???s Hard-to-Abuse Narcotic Painkiller

FDA Approves Purdue Pharma’s Hard-to-Abuse Narcotic PainkillerJuly 28, 2014By Renee Morad , BioSpace.com Breaking News StaffThe Food and Drug Administration approved a drug combining oxycodone and naloxone that is designed to discourage abuse by those ... [Published BioSpace - Jul 28 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 4 reports

Harder-to-abuse oxycodone painkiller approved

FDA has approved a new oxycodone painkiller that’s designed to be more difficult for drug abusers to exploit.Targiniq ER (Purdue Pharma) is an extended-release tablet that combines oxycodone, the active ingredient in OxyContin, with the drug naloxone. ... [Published Drugtopics.com - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 10 reports

Extended-Release Oxycodone With Abuse-Deterrent Properties Gets FDA Nod

Product can still be abused when taken orallyThe FDA has approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets, Purdue Pharma), an extended-release/long-acting (ER/LA) opioid analgesic, to treat pain that is ... [Published P&T Community - Jul 24 2014]
Entities: Oxycodone, Opioid, Abuse
First reported May 29 2014 - Updated May 30 2014 - 2 reports

ExtraHop raises $41M to help businesses make sense of their wire data

Image Credit: grover_net/Flickr ExtraHop , a company that provides wire data analytics for IT operations, announced today that it has raised $41 million in a third round of funding led by Technology Crossover Ventures. The term “wire data” doesn’t ... [Published Venturebeat - May 29 2014]

Quotes

S. Patent & Trademark Office: "In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C …"
• How do human review results compare to predicative coding? Find out during " Anything You Can Do I Can Do Better… Predictive Coding vs. Human Review ,” at 3:30 p.m. in Canal CD. Patrick Oot hosts the panel, which will highlight results from a recent Electronic Discovery Institute predictive coding study, among other EDD-related information and data."
...needs of appropriate chronic pain patients," said Todd Baumgartner, M D , MPH, vice president of R&D and chief medical officer at Purdue Pharma. "The introduction of the 7.5mcg/hour dosage strength further demonstrates Purdue's ongoing commitment to the management of chronic pain."
"If we really want to turn this epidemic around, the most important thing is to stop creating new cases of addiction" stated Dr. Kolodny to the LA Times. "Coming up with new gimmicks isn't going to help."

More Content

All (95) | News (65) | Reports (0) | Blogs (28) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
The DEA, narcotic abuse, and a terrible solutio... [Published American Council On Science & Health - Aug 22 2014]
US DEA publishes final rule to reschedule hydro... [Published Pharma Letter - Aug 22 2014]
Nektar Therapeutics Has More To Give [Published Seeking Alpha - Aug 21 2014]
US Patent Issued to Purdue Pharma on Aug. 19 fo... [Published HighBeam Research - Aug 20 2014]
A Pharmacist’s Guide to the Emerging Abuse Dete... [Published Pharmacy Times - Aug 19 2014]
Canada slow to respond to opioid addiction crisis [Published Globe and Mail - Aug 14 2014]
Zogenix: Beaten And Battered, But Not Out [Published Seeking Alpha - Aug 14 2014]
All Star E-Discovery Panels at ILTA [Published Law Technology News - Aug 12 2014]
Butrans Transdermal System CIII receives new do... [Published Center Watch - Aug 09 2014]
Painkillers Killing Our Vets [Published American Free Press - Aug 08 2014]
Doctors deride new 'abuse-resistant' painkiller... [Published Natural News - Aug 08 2014]
Marijuana Legalization: Pharmaceuticals, Alcoho... [Published International Business Times - Aug 06 2014]
Zogenix seeks partner, steers Zohydro marketing... [Published FiercePharma - Aug 06 2014]
Justin Chickles Joins myoscience as Vice Presid... [Published Stock Nod - Aug 06 2014]
Prescription drug abuse affects one in four of ... [Published Pharma Letter - Aug 05 2014]
Daily Decision Service Alert: Vol. 23, No. 144 ... [Published New Jersey Law Journal - Aug 04 2014]
New painkiller created to discourage abuse [Published Delco Times - Aug 03 2014]
New products for pharmacists 08-10-2014 [Published Drugtopics.com - Jul 31 2014]
The Galien Foundation Announces 2014 Prix Galie... [Published TickerTech.com - Jul 31 2014]
FDA Grants Priority Review Designation for Purd... [Published HighBeam Research - Jul 30 2014]
FDA Approves Purdue Pharma’s Abuse-Deterrent Pa... [Published FDA News - Jul 30 2014]
Global Infection Prevention and Control Market ... [Published MarketResearch.com - Jul 29 2014]
FDA Approves Purdue Pharma L.P.???s Hard-to-Abu... [Published BioSpace - Jul 28 2014]
FDA Accredits New Combination Painkillers Desig... [Published MedIndia - Jul 26 2014]
Harder-to-abuse oxycodone painkiller approved [Published Drugtopics.com - Jul 25 2014]
FDA approves Purdue’s abuse-deterrent opioid Ta... [Published Pharma Letter - Jul 25 2014]
FDA approves pain drug that has reduced risk of... [Published PMLive - Jul 25 2014]
Studies Examining the Relationship between the... [Published Journal of Medicinal Chemistry - Jul 25 2014]
FDA approves a new painkiller [Published Medical Marketing And Media - Jul 24 2014]
Even a Light Rain Can Send Raw Sewage Into New ... [Published Fair Warning - Jul 24 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Purdue Pharma gets FDA approval for 7.5 mcg/hou... [Published PBR - News - Jul 21 2014]
Purdue Pharma has announced that the US Food & Drug Administration (FDA) has approved a new 7.5 mcg/hour dosage strength of Butrans (buprenorphine) Transdermal System CIII. Five strengths of Butrans will now be available: 5 mcg/hour, 7.5 mcg/hour, 10 ...
Purdue Pharma L.P. Receives FDA Approval for 7.... [Published PR Newswire: Policy & Public Interest - Jul 16 2014]
STAMFORD, Conn., July 16, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) approved a new 7.5 mcg/hour dosage strength of Butrans® (buprenorphine) Transdermal System CIII. Five strengths of Butrans will ...
FDA Grants Priority Review Designation for Purd... [Published PR Newswire: Policy & Public Interest - Jul 08 2014]
STAMFORD, Conn., July 8, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) has granted Priority Review designation for the company's once-daily, single-entity hydrocodone bitartrate tablet (HYD).  This ...
Prescription Opioid Makers Are Big Donors to An... [Published Firedoglake - Jul 08 2014]
On average, opioid prescription rates are noticeably lower in medical marijuana states.  Coincidence? A fascinating article highlights many of the conflicts of interest at the heart of top anti-marijuana legalization groups  in the country : The ...
MS CONTIN (Morphine Sulfate) Tablet, Film Coate... [Published DailyMed Drug Label Updates for the last seven ... - Jun 22 2014]
Updated Date: Jun 19, 2014 EST ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Purdue Pharma L.P., a Leading Pharmaceutical Co... [Published Financial Services - Jun 18 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.